{"pmid":32220278,"title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","text":["Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","Lancet","Ritchie, Andrew I","Singanayagam, Aran","32220278"],"journal":"Lancet","authors":["Ritchie, Andrew I","Singanayagam, Aran"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220278","week":"202014|Mar 30 - Apr 05","doi":"10.1016/S0140-6736(20)30691-7","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1662624089064341504,"score":7.2532344,"similar":[{"pmid":32202240,"title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","text":["COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.","Clin Exp Rheumatol","Sarzi-Puttini, Piercarlo","Giorgi, Valeria","Sirotti, Silvia","Marotto, Daniela","Ardizzone, Sandro","Rizzardini, Giuliano","Antinori, Spinello","Galli, Massimo","32202240"],"abstract":["A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs."],"journal":"Clin Exp Rheumatol","authors":["Sarzi-Puttini, Piercarlo","Giorgi, Valeria","Sirotti, Silvia","Marotto, Daniela","Ardizzone, Sandro","Rizzardini, Giuliano","Antinori, Spinello","Galli, Massimo"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202240","week":"202013|Mar 23 - Mar 29","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1662334543301967872,"score":44.165226}]}